Gland Pharma (NSE:GLAND) 6-Month Price Index: 1.78 (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLAND Gland Pharma Ltd NSE:GLAND
81 GF Score
Price ₹2,895.50
GF Value ₹2,266.18
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Gland Pharma 6-Month Price Index?

Gland Pharma NSE:GLAND -0.92% 81 6-Month Price Index is 1.78 as of Sep. 16, 2026. GuruFocus rates NSE:GLAND with a GF Score™ of 81/100 and a GF Value™ of ₹2,266.18 (Modestly Overvalued). The stock has 6 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-16), Gland Pharma's 6-Month Price Index is 1.78.

Gland Pharma  (NSE:GLAND) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Gland Pharma 6-Month Price Index Related Terms

NSE:GLAND vs ZTS: 6-Month Price Index Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NSE:GLAND
81GF Score
Gland Pharma Ltd NSE:GLAND
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma  (NSE:GLAND) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.78 mean?
Gland Pharma (NSE:GLAND) has a 6-Month Price Index of 1.78 as of Sep. 16, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Gland Pharma and its competitors.
Is Gland Pharma's 6-Month Price Index too high?
Gland Pharma's current 6-Month Price Index is 1.78. Overall, Gland Pharma has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's 6-Month Price Index compare to ZTS?
Gland Pharma's 6-Month Price Index of 1.78 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Drug Manufacturers company?
A good 6-Month Price Index depends on the Drug Manufacturers industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Gland Pharma and its competitors. Gland Pharma's current 6-Month Price Index is 1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,266.18, compared to a current price of ₹2,895.50 — trading 27.8% above its estimated fair value. The current 6-Month Price Index is 1.78. Gland Pharma's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current 6-Month Price Index is 1.78 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,895.50 is trading 27.8% above its estimated GF Value™ of ₹2,266.18. GuruFocus considers Gland Pharma to be Modestly Overvalued.

Key valuation signals for NSE:GLAND:

  • 6-Month Price Index: 1.78
  • GF Value™: ₹2,266.18 vs. price of ₹2,895.50 (27.8% above fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
81GF Score

Get the complete analysis for NSE:GLAND

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,895.50
Price
₹2,266.18
GF Value